Gold prices steady amid Fed rate cut hopes; Trump-Putin talks awaited
SYDNEY - Little Green Pharma Ltd (ASX:LGP) has reported a significant year-on-year revenue increase in its latest quarterly activities report and Appendix 4C, ending March 31, 2025, according to a press release by SEED Innovations Limited, an investor in LGP.
SEED Innovations, which trades on the AIM under the ticker SEED and holds a 2.43% stake in LGP, highlighted the latter’s robust double-digit growth. LGP’s unaudited revenue reached $36.6 million for the financial year 2025, marking over 40% growth from the previous year. The acquisition of Health House contributed an additional $0.8 million in third-party product sales within two months post-acquisition.
The quarterly revenue for LGP stood at $9.6 million, up more than 30% from the same period last year, with March witnessing a record $4.0 million in sales. Cash receipts, including Health House, totaled $10.3 million, nearly a 30% increase from the prior corresponding period.
SEED CEO Ed McDermott commented on LGP’s performance, noting the company’s solid financial position with net tangible assets surpassing its enterprise value and minimal long-term debt. He also pointed out the increasing sales momentum in Germany and the UK as a reinforcement of LGP’s strategic direction.
LGP’s successful activities also included the extension of NAB loan facilities to June 30, 2027, and the strengthening of its board with new appointments. The company’s cash in the bank was reported at $2.4 million.
Additionally, LGP has been involved in legislative processes and clinical studies, with the French national cannabis legislation submitted to the European Commission and commercial access expected late in the calendar year 2025 or early 2026. The company also released 12-month QUEST results, which were published in the PLOS One journal, demonstrating the long-term efficacy of LGP medicinal cannabis for various chronic conditions.
This announcement is based on a press release statement and contains information that can be verified independently. It is intended to provide a factual report on LGP’s financial performance and strategic developments without endorsing the claims or projecting future outcomes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.